These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

982 related items for PubMed ID: 18568764

  • 21. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
    Freidlin B, Simon R.
    Clin Cancer Res; 2005 Nov 01; 11(21):7872-8. PubMed ID: 16278411
    [Abstract] [Full Text] [Related]

  • 22. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR, Maitland ML, Ratain MJ.
    Cancer J; 2009 Nov 01; 15(5):426-30. PubMed ID: 19826363
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Endpoints for assessing drug activity in clinical trials.
    Pazdur R.
    Oncologist; 2008 Nov 01; 13 Suppl 2():19-21. PubMed ID: 18434634
    [Abstract] [Full Text] [Related]

  • 29. Clinical trial designs for multiple myeloma.
    Hoering A, Crowley J.
    Clin Adv Hematol Oncol; 2007 Apr 01; 5(4):309-16. PubMed ID: 17607290
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Optimizing randomized phase II trials assessing tumor progression.
    Stone A, Wheeler C, Carroll K, Barge A.
    Contemp Clin Trials; 2007 Feb 01; 28(2):146-52. PubMed ID: 16807129
    [Abstract] [Full Text] [Related]

  • 33. Does the Prentice criterion validate surrogate endpoints?
    Berger VW.
    Stat Med; 2004 May 30; 23(10):1571-8. PubMed ID: 15122737
    [Abstract] [Full Text] [Related]

  • 34. Novel designs and end points for phase II clinical trials.
    Adjei AA, Christian M, Ivy P.
    Clin Cancer Res; 2009 Mar 15; 15(6):1866-72. PubMed ID: 19276272
    [Abstract] [Full Text] [Related]

  • 35. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep 15; 96(18):1355. PubMed ID: 15367566
    [No Abstract] [Full Text] [Related]

  • 36. Adaptive methods: telling "the rest of the story".
    Emerson SS, Fleming TR.
    J Biopharm Stat; 2010 Nov 15; 20(6):1150-65. PubMed ID: 21058111
    [Abstract] [Full Text] [Related]

  • 37. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [Abstract] [Full Text] [Related]

  • 38. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
    Sakamoto J, Morita S.
    Nagoya J Med Sci; 2007 Jan 01; 69(1-2):9-16. PubMed ID: 17378175
    [Abstract] [Full Text] [Related]

  • 39. Randomized phase II trials: misleading and unreliable.
    Stewart DJ.
    J Clin Oncol; 2010 Nov 01; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract] [Full Text] [Related]

  • 40. Clinical trial design in hepatocellular carcinoma.
    Johnson PJ, Billingham LJ.
    Best Pract Res Clin Gastroenterol; 2005 Feb 01; 19(1):119-27. PubMed ID: 15757808
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.